STOCK TITAN
  1. Home
  2. News
  3. SMTI

Sanara MedTech Inc. - $SMTI STOCK NEWS

Welcome to our dedicated page for Sanara MedTech news (Ticker: $SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara MedTech stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sanara MedTech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sanara MedTech's position in the market.

News
Sanara MedTech Inc. Announces First Quarter Earnings Release and Conference Call Dates
Rhea-AI Summary

Sanara MedTech Inc., a medical technology company, announced the details for the release of its first quarter earnings for the period ending March 31, 2024. The company will issue its earnings release on May 13, 2024, and host a conference call on May 14, 2024, at 9:00 a.m. Eastern Time. Investors can access the call via phone or webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
earnings
-
News
Sanara MedTech Inc. Announces $55 Million Debt Facility
Rhea-AI Summary
Sanara MedTech Inc. announced a $55 million non-dilutive term loan agreement with CRG Servicing to support growth initiatives. The company received $15 million at closing and can access an additional $40 million. The funds will be used for acquisitions, investments, working capital, and general corporate purposes. Sanara is also in talks for a $10 million revolving line of credit. The partnership with CRG aims to enhance clinical outcomes and reduce healthcare costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.63%
Tags
none
-
News
Sanara MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer
Rhea-AI Summary
Sanara MedTech Inc. appoints Jake Waldrop as COO and Tyler Palmer as Chief Corporate Development and Strategy Officer. Both bring extensive experience in the medical device and healthcare sectors, aiming to enhance financial and clinical outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
News
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results
Rhea-AI Summary
Sanara MedTech Inc. reports strong financial results for Q4 2023 and full year 2023, with significant sales growth and operational achievements. The Company achieved record sales of $17.7 million in Q4 2023 and net revenues of $65.0 million for full year 2023, representing a 42% increase from the prior year. Sanara also announced key strategic milestones, including the acquisition of CellerateRX assets, launch of ALLOCYTE Plus product, and commercialization of BIASURGE. The Company's focus on developing transformative technologies in the medical field positions it for continued growth in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
earnings
-
News
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release and Conference Call Dates
Rhea-AI Summary
Sanara MedTech Inc. announces the release of its financial results for the quarter and year ended December 31, 2023. The company will issue its earnings release on March 25, 2024, and host a conference call on March 26, 2024, to discuss the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
earnings
-
News
Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2023
Rhea-AI Summary
Sanara MedTech Inc. announces unaudited preliminary results for Q4 and full-year 2023, showing a 15.5% increase in net revenue for Q4 and a 41.8% increase for the full year. Cash position stands at $5.1 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
earnings
News
Sanara MedTech Inc. Announces Exclusive License Agreement for Patented Collagen Peptides
Rhea-AI Summary
Sanara MedTech Inc. (NASDAQ: SMTI) has signed an exclusive license agreement with Tufts University to develop and commercialize patented technology covering 18 unique collagen peptides. The agreement includes one U.S. patent, one granted European patent, one Canadian patent pending, and one Patent Cooperation Treaty patent pending. Sanara has formed a new subsidiary, Sanara Collagen Peptides, LLC, and has issued 10% of SCP’s outstanding units to Tufts. SCP has exclusive rights to develop and commercialize new products based on the licensed patents and patents pending. SCP will pay royalties to Tufts based on net sales of licensed products and technologies. The company aims to expand its product offering of collagen products and sees significant opportunities to improve outcomes and advance patient care while reducing healthcare system costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.08%
Tags
none
-
News
Sanara MedTech Inc. Announces the Publication of a 5,335 Patient Study Demonstrating a Significant Reduction in Surgical Site Infections When Activated Collagen (CellerateRX® Surgical Powder) Was Used to Promote Wound Healing
Rhea-AI Summary
Sanara MedTech Inc. (NASDAQ: SMTI) announced the publication of a retrospective study on CellerateRX Surgical Powder in the Journal of Surgery. The study demonstrates the significant impact of CellerateRX in reducing surgical site infections and promoting wound healing in elective surgery patients. Sanara's CEO believes that these results align with the company's mission of improving outcomes while lowering costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
-
News
Sanara MedTech Inc. Announces Third Quarter 2023 Results
Rhea-AI Summary
Sanara MedTech Inc. (NASDAQ: SMTI) announced its strategic, operational, and financial results for Q3 2023, including record sales, narrowing net loss, and positive Adjusted EBITDA. The company completed the acquisition of collagen business assets and launched ALLOCYTE Plus and BIASURGE products. Net revenue for Q3 2023 was $16.0 million, a 23% increase from the prior year period. The Company's loss before income taxes for Q3 2023 was $1.1 million compared to $3.2 million in Q3 2022. Adjusted EBITDA was $0.3 million for Q3 2023 compared to negative $1.6 million in Q3 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.36%
Tags
earnings
News
Sanara MedTech Inc. Announces Third Quarter Earnings Release and Conference Call Dates
Rhea-AI Summary
Sanara MedTech Inc. announced details for the release of its Q3 2023 results. The earnings release will be on November 13, 2023, followed by a conference call on November 14, 2023. The company's focus is on developing and commercializing transformative technologies in the medical field. Investors can access the conference call through a toll-free number or a live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.05%
Tags
earnings
Stock SMTI logo
Sanara MedTech Inc.

Nasdaq:SMTI

SMTI Rankings

#3508 Ranked by Market Cap
#2621 Ranked by Stock Gains
N/A Ranked by Dividends

SMTI Stock Data

279.72M
3.46M
60.55%
8.42%
1.65%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
FORT WORTH

About SMTI

wound management technologies, inc., through its subsidiary, wound care innovations, llc, distributes collagen-based wound care products in the united states. the company holds worldwide license to certain technologies and processes related to a collagen-based wound care product formulation under the brand name celleraterx. it markets celleraterx for pressure ulcers, diabetic ulcers, surgical wounds, ulcers due to arterial insufficiency, traumatic wounds, first and second degree burns, and superficial wounds. the company offers celleraterx in gel and powder forms. it serves healthcare providers, such as physicians, clinics, and hospitals. wound management technologies was formerly known as mb software corporation. the company was founded in 1982 and is based in fort worth, texas.